Pharmacokinetics of gefitinib predicts the antitumor activity for advanced non-small cell lung cancer (NSCLC).

被引：0
|
作者：
Nakamura, Y.
Sano, K.
Fukuda, M.
Takatani, H.
Nagashima, S.
Kinoshita, A.
Fukuda, M.
Soda, H.
Oka, M.
Kohno, S.
机构：
[1] Goto Cent Hosp, Goto, Japan
[2] Meiji Pharmaceut Univ, Tokyo, Japan
[3] Nagasaki Thorac Oncol Grp, Nagasaki, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：81S / 81S
页数：1
相关论文
共 50 条
  • [41] Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): Study of a comprehensive panel of molecular markers
    Tiseo, Marcello
    Rossi, Giulio
    Capelletti, Marzia
    Sartori, Giuliana
    Spiritelli, Elena
    Marchioni, Alessandro
    Bozzetti, Cecilia
    De Palma, Giuseppe
    Lagrasta, Costanza
    Campanini, Nicoletta
    Camisa, Roberta
    Boni, Luca
    Franciosi, Vittorio
    Rindi, Guido
    Ardizzoni, Andrea
    LUNG CANCER, 2010, 67 (03) : 355 - 360
  • [42] Gefitinib therapy for non-small cell lung cancer
    Birnbaum A.
    Ready N.
    Current Treatment Options in Oncology, 2005, 6 (1) : 75 - 81
  • [43] Determinants of Gefitinib toxicity in advanced non-small cell lung cancer (NSCLC): a pharmacogenomic study of metabolic enzymes and transporters
    Y Ma
    S Xin
    M Huang
    Y Yang
    C Zhu
    H Zhao
    Y Zhang
    L Chen
    Y Zhao
    J Li
    W Zhuang
    X Zhu
    L Zhang
    X Wang
    The Pharmacogenomics Journal, 2017, 17 : 325 - 330
  • [44] Correlation of gefitinib and its metabolites with gefitinib induced rash in patients with non-small cell lung cancer (NSCLC).
    Guan, Shaoxing
    Chen, Xi
    Huang, Min
    Zhang, Li
    Wang, Xueding
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [45] Gefitinib in patients with advanced non-small cell lung cancer (NSCLC): The expanded access protocol experience at the University of Pennsylvania
    Veronese, ML
    Algazy, K
    Bearn, L
    Eaby, B
    Alavi, J
    Evans, T
    Stevenson, JP
    Shults, J
    CANCER INVESTIGATION, 2005, 23 (04) : 296 - 302
  • [46] Determinants of Gefitinib toxicity in advanced non-small cell lung cancer (NSCLC): a pharmacogenomic study of metabolic enzymes and transporters
    Ma, Y.
    Xin, S.
    Huang, M.
    Yang, Y.
    Zhu, C.
    Zhao, H.
    Zhang, Y.
    Chen, L.
    Zhao, Y.
    Li, J.
    Zhuang, W.
    Zhu, X.
    Zhang, L.
    Wang, X.
    PHARMACOGENOMICS JOURNAL, 2017, 17 (04): : 325 - 330
  • [47] Study of EGFR signaling on buccal mucosa and tumor cells as surrogate markers of gefitinib activity in advanced non-small cell lung cancer (NSCLC)
    Tiseo, M
    Loprevite, M
    Chiaramondia, M
    Naldi, N
    Nizzoli, R
    Bozzetti, C
    Capelletti, M
    Spiritelli, E
    Camisa, R
    Grossi, F
    Dadati, P
    Kunkl, A
    Rindi, G
    Franciosi, V
    Ardizzoni, A
    ANNALS OF ONCOLOGY, 2006, 17 : 33 - 33
  • [48] Advanced non-small cell Lung Cancer (NSCLC) Nivolumab in advanced NSCLC with Squamous Epithelial Histology
    Sankawa, Yuri
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 (03) : 149 - 149
  • [49] Molecular characteristics of non-small cell lung cancer (NSCLC) patients sensitive to gefitinib.
    Pao, W
    Zakowski, M
    Cordon-Cardo, C
    Ben-Porat, L
    Kris, MG
    Miller, VA
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 623S - 623S
  • [50] Pharmacokinetics of gefitinib in elderly patients with EGFR-mutated advanced non-small cell lung cancer: a prospective study
    Yuta Nio
    Hiroo Ishida
    Natsumi Matsumoto
    Sojiro Kusumoto
    Yutaro Kubota
    Takuya Tsunoda
    Yasutsuna Sasaki
    Ken-ichi Fujita
    BMC Pulmonary Medicine, 22
12345